Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial

[1]  P. Anderson,et al.  Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy , 2020, Nutrients.

[2]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[3]  Kheir M. Al-Kodmany.  Preliminary Findings , 2020, The Urban Book Series.

[4]  Y. Lai,et al.  Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer , 2019, Medicine.

[5]  A. Naing.  Being realistic and optimistic in curing cancer , 2018, Journal of Immunotherapy and Precision Oncology.

[6]  Kanyilmaz Gul,et al.  The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy. , 2017, Clinical nutrition.

[7]  Hyeyoung Kim,et al.  The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases , 2017, International journal of molecular sciences.

[8]  James W Snider,et al.  Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. , 2017, Translational lung cancer research.

[9]  C. Xie,et al.  Weight loss predicts poor prognosis in patients treated with concurrent chemoradiotherapy for stage III non-small cell lung cancer , 2017 .

[10]  A. Fairchild,et al.  Radiation-induced esophagitis in lung cancer , 2016, Lung Cancer.

[11]  M. Ballesteros-Pomar,et al.  Efficacy of Glutamine in the Prevention of Oral Mucositis and Acute Radiation-Induced Esophagitis: A Retrospective Study , 2013, Nutrition and cancer.

[12]  E. Topkan,et al.  Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer , 2012, BMC Cancer.

[13]  Maria Werner-Wasik,et al.  Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. , 2011, Clinical lung cancer.

[14]  C. Onal,et al.  Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. , 2009, Lung cancer.

[15]  A. Bezjak,et al.  Palliative thoracic radiotherapy for lung cancer: a systematic review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  V. Klimberg,et al.  Effect of Glutamine on Gut Glutathione Fractional Release in the Implanted Tumor Model , 2007, Nutrition and cancer.

[17]  N. Rodríguez,et al.  Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. , 2007, International journal of radiation oncology, biology, physics.

[18]  Tito R Mendoza,et al.  Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module , 2007, Head & neck.

[19]  J. Howington,et al.  Phase I Clinical Trial of Concurrent Paclitaxel, Carboplatin, and External Beam Chest Irradiation with Glutamine in Patients with Locally Advanced Non-Small Cell Lung Cancer , 2007, Cancer investigation.

[20]  D. Howell.  The role of radiation therapy in the palliation of gastrointestinal malignancies. , 2006, Gastroenterology clinics of North America.

[21]  R. Komaki,et al.  Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Herbst,et al.  Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. , 2004, International journal of radiation oncology, biology, physics.

[23]  P. Wischmeyer,et al.  Prevention of chemotherapy and radiation toxicity with glutamine. , 2003, Cancer treatment reviews.

[24]  M. Synodinou,et al.  Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.

[25]  L. Chew,et al.  Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Senzer.  A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. , 2002, Seminars in oncology.

[27]  N. Senzer.  Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lu , 2002 .

[28]  H. Athanassiou,et al.  Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[29]  W. Sause,et al.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. , 2000, International journal of radiation oncology, biology, physics.

[30]  C. Cleeland,et al.  Assessing symptom distress in cancer patients , 2000 .

[31]  C. Cleeland,et al.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. , 2000, Cancer.

[32]  Choi Sc,et al.  Monitoring clinical trials based on predictive probability of significance. , 1989 .

[33]  S. C. Choi,et al.  Monitoring clinical trials based on predictive probability of significance. , 1989, Biometrics.